NASDAQ : FBLG
FibroBiologics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.40M |
| Enterprise Value | 4.35M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 6.96M |
| Shares Outstanding | 6.96M |
| Shares Change (YoY) | +112.97% |
| Shares Change (QoQ) | +66.25% |
| Owned by Insiders (%) | 8.87% |
| Owned by Institutions (%) | 6.95% |
| Float | 5.42M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.64 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -77.81 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -660.08% |
| Return on Assets (ROA) | -95.77% |
| Return on Invested Capital (ROIC) | -117.92% |
| Return on Capital Employed (ROCE) | -292.67% |
| Weighted Average Cost of Capital (WACC) | 13.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.74 |
| 52-Week Price Change | -88.30% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 2.35 |
| Relative Strength Index (RSI) | 35.83 |
| Average Volume (20 Days) | 121,709 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 330,551 |
| Short Previous Month | 522,114 |
| Short % of Shares Out | 4.75% |
| Short % of Float | 6.09% |
| Short Ratio (days to cover) | 2.32 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.73M |
| Pretax Income | -18.14M |
| Net Income | -18.14M |
| EBITDA | -16.47M |
| EBIT | -16.73M |
| Earnings Per Share (EPS) | -$4.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.52M |
| Total Debt | 1.46M |
| Net Cash | 2.05M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 4.64M |
| Book Value Per Share | 0.76 |
| Working Capital | 3.64M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -14.79M |
| Capital Expenditures | -6,000 |
| Depreciation & Amortization | 263,000 |
| Net Borrowing | -3.28M |
| Free Cash Flow | -14.80M |
| FCF Per Share | -$2.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -112.97% |
| Shareholder Yield | -112.97% |
| Earnings Yield | -517.95% |
| FCF Yield | -229.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.50 |
| Price Target Difference | 1,258.55% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |